中国临床药学杂志

参考文献

[1] CAO Y, GU H Y, HUANG Z D, et al. Impact of enhanced recovery after surgery on postoprative recovery for pancreaticoduodenectomy:pooled analysis of observational study[J]. Front Oncol, 2019, 9:687.

[2]中华医学会呼吸病学分会感染学组.中国成人医院获得性肺炎与呼吸机相关性肺炎诊断和治疗指南(2018年版)[J].中华结核和呼吸杂志, 2018, 41(4):255.

[3] BORTOLOTTIP, DELPIERREC, GUERNRL, et al. High incidence of post operative in fection safter pancreaticoduodenectomy:a need for perioperative anti-infectious strategies[J]. Infect Dis Now, 2021, 51(5):456.

[4]中国医药教育协会感染疾病专业委员会.抗菌药物药代动力学/药效学理论临床应用专家共识[J].中华结核和呼吸杂志, 2018,41(6):409.

[5]国家卫生健康委合理用药专家委员会.国家抗微生物治疗指南(第3版)[M].北京:人民卫生出版社, 2023:21-22.

[6]国家卫生健康委合理用药专家委员会.耐药革兰氏阴性菌感染诊疗手册(第2版)[M].北京:人民卫生出版社, 2022:49-125.

[7]戴维·吉尔伯特.桑福德抗微生物治疗指南(第50版)[M].范洪伟,译.北京:中国协和医科大学出版社, 2021:42-43.

[8]中国碳青霉烯耐药肠杆菌科细菌感染诊治与防控专家共识编写组,中国医药教育协会感染疾病专业委员会,中华医学会细菌感染与耐药防控专业委员会.中国碳青霉烯耐药肠杆菌科细菌感染诊治与防控专家共识[J].中华医学杂志, 2021, 101(36):2850.

[9] RODRíGUEZ-GASCóN A, CANUT-BLASCO A. Deciphering pharmacokinetics and pharmacodynamics of fosfomycin[J]. Rev Esp Quimioter, 2019, 32(Suppl 1):19.

[10] CAMARLINGHI G, PARISIO E M, ANTONELLI A, et al.Discrepancies in fosfomycin susceptibility testing of KPC-producing Klebsiella pneumoniae with various commercial methods[J].Diagn Microbiol Infect Dis, 2019, 93(1):74.

[11] ZENG M, XIA J, ZONG Z Y, et al. Guidelines for the diagnosis,treatment, prevention and control of in fection scaused by carbapenem-resistant gram-negative bacilli[J]. Wei Mian Yu Gan Ran Za Zhi, 2023, 56(4):653.

[12] HUANG L, WANG M Y, SUN L Y. Synergy testing by E-test and microdilution checkerboard for fosfomycin combined with tigecycline against KPC-producing Klebsiella pneumoniae[J].Clin Lab, 2019, 65(12):2369.

[13] NI W T, LI G B, ZHAO J, et al. Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae[J]. Infect Dis, 2018, 50(7):507.